SXI Life Sciences
7.772,36
PKT
-3,32
PKT
-0,04
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 17.10.19 | Roche overweight | Morgan Stanley | |
| 17.10.19 | Roche Neutral | Credit Suisse Group | |
| 17.10.19 | Roche buy | Deutsche Bank AG | |
| 17.10.19 | Roche overweight | Barclays Capital | |
| 17.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.10.19 | Roche overweight | JP Morgan Chase & Co. | |
| 17.10.19 | Roche buy | Goldman Sachs Group Inc. | |
| 16.10.19 | Roche overweight | Morgan Stanley | |
| 16.10.19 | Roche overweight | JP Morgan Chase & Co. | |
| 16.10.19 | Roche buy | Deutsche Bank AG | |
| 16.10.19 | Roche buy | Jefferies & Company Inc. | |
| 16.10.19 | Roche buy | Goldman Sachs Group Inc. | |
| 16.10.19 | Roche buy | UBS AG | |
| 15.10.19 | Roche buy | Jefferies & Company Inc. | |
| 11.10.19 | Roche overweight | JP Morgan Chase & Co. | |
| 08.10.19 | Roche buy | Goldman Sachs Group Inc. | |
| 07.10.19 | Novartis Neutral | UBS AG | |
| 07.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 07.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 02.10.19 | Roche overweight | JP Morgan Chase & Co. | |
| 30.09.19 | Roche buy | Deutsche Bank AG | |
| 30.09.19 | Roche overweight | JP Morgan Chase & Co. | |
| 17.09.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 17.09.19 | Roche buy | Goldman Sachs Group Inc. | |
| 17.09.19 | Roche buy | Deutsche Bank AG | |
| 17.09.19 | Roche buy | UBS AG | |
| 17.09.19 | Roche overweight | JP Morgan Chase & Co. | |
| 16.09.19 | Roche buy | UBS AG | |
| 16.09.19 | Roche buy | Deutsche Bank AG | |
| 16.09.19 | Novartis Hold | Deutsche Bank AG | |
| 13.09.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 13.09.19 | Novartis buy | Merrill Lynch & Co., Inc. | |
| 13.09.19 | Roche buy | Merrill Lynch & Co., Inc. | |
| 13.09.19 | Roche overweight | JP Morgan Chase & Co. | |
| 10.09.19 | Novartis Neutral | UBS AG | |
| 09.09.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 09.09.19 | Roche overweight | Barclays Capital | |
| 09.09.19 | Novartis Hold | Deutsche Bank AG | |
| 05.09.19 | Roche overweight | JP Morgan Chase & Co. |